Disappearance of bone metastases in chemotherapy‑resistant gastric cancer treated with antigen peptide‑pulsed dendritic cell‑activated cytotoxic T lymphocyte immunotherapy: A case report

Du,Juan; Wei,Jia; Yang,Yang; Su,Shu; Shao,Jie; Chen,Fangjun; Meng,Fanyan; Zou,Zhengyun; Liu,Baorui

doi:10.3892/ol.2018.8781

Disappearance of bone metastases in chemotherapy‑resistant gastric cancer treated with antigen peptide‑pulsed dendritic cell‑activated cytotoxic T lymphocyte immunotherapy: A case report

Authors:
- Juan Du
- Jia Wei
- Yang Yang
- Shu Su
- Jie Shao
- Fangjun Chen
- Fanyan Meng
- Zhengyun Zou
- Baorui Liu
View Affiliations

Affiliations: The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu 210008, P.R. China
Published online on: May 22, 2018 https://doi.org/10.3892/ol.2018.8781
Pages: 875-881
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The adoptive transfer of cytotoxic T lymphocytes (CTLs) stimulated by specific tumor antigen peptide‑pulsed dendritic cells (DCs) is one of the most promising immunotherapeutic strategies currently available for patients with gastric cancer (GC). The present case report describes a patient with chemotherapy‑resistant stage IV GC with multiple bone metastases, who had been treated with antigen peptide‑pulsed DC‑CTLs. DCs and CTLs were transfused into the patient subcutaneously and intravenously with simultaneous oral administration of low‑dose cyclophosphamide. Following 3 cycles of combination therapy, marked remission regarding the number of metastatic bone lesions was achieved, confirmed by the use of enhanced computerized tomography, computerized tomography and magnetic resonance imaging. After 1 year, 8 cycles of adoptive immunotherapy were administered, and a further decrease in the number of metastatic bone lesions was observed in addition to a marked improvement in the patient's quality of life. Therefore, personalized antigen peptide‑pulsed DC‑CTLs combined with oral administration of low‑dose cyclophosphamide may serve as a promising anticancer therapy to eradicate tumor cells, and therefore this approach is recommended for future cases of a similar nature.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Wesolowski R, Lee C and Kim R: Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol. 10:903–912. 2009. View Article : Google Scholar : PubMed/NCBI
3	Kim HJ and Oh SC: Novel systemic therapies for advanced gastric cancer. J Gastric Cancer. 18:1–19. 2018. View Article : Google Scholar : PubMed/NCBI
4	Satolli MA, Buffoni L, Spadi R and Roato I: Gastric cancer: The times they are a-changin’. World J Gastrointest Oncol. 7:303–316. 2015. View Article : Google Scholar : PubMed/NCBI
5	Gattinoni L, Powell DJ Jr, Rosenberg SA and Restifo NP: Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol. 6:383–393. 2006. View Article : Google Scholar : PubMed/NCBI
6	Yee C: The use of endogenous T cells for adoptive transfer. Immunol Rev. 257:250–263. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ernst B and Anderson KS: Immunotherapy for the treatment of breast cancer. Curr Oncol Rep. 17:52015. View Article : Google Scholar : PubMed/NCBI
8	Sheu BC, Chiou SH, Chang WC, Chow SN, Lin HH, Chen RJ, Huang SC, Ho HN and Hsu SM: Integration of high-risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma. Clin Immunol. 115:295–301. 2005. View Article : Google Scholar : PubMed/NCBI
9	Watanabe Y, Saito M, Saito K, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, et al: Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncol Lett. 15:2756–2762. 2018.PubMed/NCBI
10	Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, Miyazaki M, Kakita N, Higashitani K, Matsubara T, et al: Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol Immunother. 60:1565–1575. 2011. View Article : Google Scholar : PubMed/NCBI
11	Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa R, et al: Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 41:1297–1304. 2012. View Article : Google Scholar : PubMed/NCBI
12	Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J and Andreesen R: Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 24:5060–5069. 2006. View Article : Google Scholar : PubMed/NCBI
13	Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, et al: Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptid. J Immunother. 30:762–772. 2007. View Article : Google Scholar : PubMed/NCBI
14	Strober W: Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 111:A3.B.1–3. 2015. View Article : Google Scholar
15	Wang M, Yin B, Wang HY and Wang RF: Current advances in T-cell-based cancer immunotherapy. Immunotherapy. 6:1265–1278. 2014. View Article : Google Scholar : PubMed/NCBI
16	Carluccio S, Delbue S, Signorini L, Setola E, Bagliani A, Della Valle A, Galli A, Ferrante P and Bregni M: Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer. J Cell Physiol. 230:1457–1465. 2015. View Article : Google Scholar : PubMed/NCBI
17	Khammari A, Labarrière N, Vignard V, Nguyen JM, Pandolfino MC, Knol AC, Quéreux G, Saiagh S, Brocard A, Jotereau F and Dreno B: Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol. 129:2835–2842. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zhang GQ, Zhao H, Wu JY, Li JY, Yan X, Wang G, Wu LL, Zhang XG, Shao Y, Wang Y and Jiao SC: Prolonged overall survival in gastric cancer patients after adoptive immunotherapy. World J Gastroenterol. 21:2777–2785. 2015. View Article : Google Scholar : PubMed/NCBI
19	Karimi S, Chattopadhyay S and Chakraborty NG: Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy. Immunology. 144:186–196. 2015. View Article : Google Scholar : PubMed/NCBI
20	Lake RA and Robinson BW: Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer. 5:397–405. 2005. View Article : Google Scholar : PubMed/NCBI
21	Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L and Chauffert B: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 56:641–648. 2007. View Article : Google Scholar : PubMed/NCBI
22	Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K, Bridgeman H, Adams R, Brewster A, Jones R, et al: Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin Cancer Res. 23:6771–6780. 2017. View Article : Google Scholar : PubMed/NCBI
23	Peng S, Lyford-Pike S, Akpeng B, Wu A, Hung CF, Hannaman D, Saunders JR, Wu TC and Pai SI: Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother. 62:171–182. 2013. View Article : Google Scholar : PubMed/NCBI
24	Suzuki E, Kapoor V, Jassar AS, Kaiser LR and Albelda SM: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721. 2005. View Article : Google Scholar : PubMed/NCBI
25	Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin GV, Shurin MR and Umansky V: Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol. 190:2464–2471. 2013. View Article : Google Scholar : PubMed/NCBI
26	Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kimura H, Matsui Y, Ishikawa A, Nakajima T, Yoshino M and Sakairi Y: Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. Cancer Immunol Immunother. 64:51–59. 2015. View Article : Google Scholar : PubMed/NCBI
28	Lutzky VP, Crooks P, Morrison L, Stevens N, Davis JE, Corban M, Hall D, Panizza B, Coman WB, Coman S and Moss DJ: Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma. Clin Vaccine Immunol. 21:256–259. 2014. View Article : Google Scholar : PubMed/NCBI
29	Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L and Apetoh L.: Trial Watch: Adoptively transferred cells for anticancer immunotherapy. Oncoimmunology. 6:e13631392017. View Article : Google Scholar : PubMed/NCBI